Table 1.
Diagnostic categories | IgH FR2 | IgH FR3 | Igκ | Bcl-1/Bcl-2 | Overall* | |||||
---|---|---|---|---|---|---|---|---|---|---|
p/t | % | p/t | % | p/t | % | p/t | % | p/t | % | |
Mature B-cell neoplasms | ||||||||||
FCL | 7 /32 | 22% | 13 /32 | 41% | 13 /32 | 41% | 7 /32 | 22% | 28 /32 | 88% |
MCL | 20 /35 | 57% | 21 /35 | 60% | 23 /35 | 66% | 11 /35 | 31% | 33 /35 | 94% |
CLL/SLL | 11 /24 | 46% | 14 /24 | 58% | 15 /24 | 63% | n /a | n/a | 21 /24 | 88% |
MZBCL | 7 /24 | 29% | 15 /24 | 63% | 9 /24 | 38% | n /a | n/a | 18 /24 | 75% |
DLCL | 12 /22 | 55% | 6 /22 | 27% | 11 /22 | 50% | n /a | n/a | 17 /22 | 77% |
Total | 57 /137 | 42% | 69 /137 | 50% | 71 /137 | 52% | n /a | n/a | 117 /137 | 85% |
Immature B-cell neoplasm | ||||||||||
B-ALL | 4 /8 | 50% | 2 /8 | 25% | 1 /8 | 13% | n /a | n/a | 5 /8 | 63% |
Nonneoplastic | ||||||||||
ALP | 9 /58 | 16% | 13 /58 | 22% | 7 /58 | 12% | n /a | n/a | 21 /58 | 36% |
RLP | 0 /18 | 0% | 1 /18 | 5% | 0 /18 | 0% | n /a | n/a | 1 /18 | 5% |
p/t, Positive/total cases; % Pos, frequency of positivity.
*Overall cases that show at least one clonal gene rearrangement product using Ig or Bcl-1/Bcl-2 PCRs.